Single‐Atom Iridium Nanozyme‐Based Persistent Luminescence Nanoparticles for Multimodal Imaging‐Guided Combination Tumor Therapy
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202402544 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Yang Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Key Laboratory of Space Bioscience & Biotechnology, Northwestern Polytechnical University, Xi'an, 710072, China. Hauptthemen laut MEDLINE: Iridium, Nanoparticles, Multimodal Imaging. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Natural Science Basic Research Plan in Shaanxi Province of China, National Undergraduate Training Programs for Innovation and Entrepreneurship, Natural Science Foundation of Fujian Province.
Abstract (Originalsprache)
Persistent luminescence nanoparticles (PLNPs) can achieve autofluorescence‐free afterglow imaging, while near‐infrared (NIR) emission realizes deep tissue imaging. Nanozymes integrate the merits of nanomaterials and enzyme‐mimicking activities with simple preparation. Here PLNPs are prepared of Zn 1.2 Ga 1.6 Ge 0.2 O 4 :Cr 0.0075 with NIR emission at 700 nm. The PLNPs are then incubated with IrCl 3 solution, and the nanoparticles are collected and annealed at 750 °C to obtain iridium@PLNPs. Iridium is observed on the PLNPs at the atomic level as a single‐atom nanozyme with peroxidase‐like catalytic activity, photothermal conversion, and computed tomography (CT) contrast capability. After coating with exosome membrane (EM), the Ir@PLNPs@EM composite exhibits long‐lasting NIR luminescence, peroxidase‐like catalytic activity, photothermal conversion, and CT contrast capability, with the targeting capability and biocompatibility from EM. Thus, NIR afterglow/photothermal/CT trimodal imaging‐guided photothermal‐chemodynamic combination therapy is realized as validated with the in vitro and in vivo inhibition of tumor growth, while toxicity and side effects are avoided as drug‐free treatment. This work offers a promising avenue for advanced single‐atom nanozyme@PLNPs to promote the development of nanozymes and PLNPs for clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Sciences, Key Laboratory of Space Bioscience & Biotechnology, Northwestern Polytechnical University, Xi'an, 710072, China.
- Department of Biological Engineering, College of Food and Biological Engineering, Jimei University, Xiamen, Fujian, 361021, China.
- Chongqing Innovation Center, Northwestern Polytechnical University, Chongqing, 401135, China.
- Institute for Frontier Medical Technology, College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai, 201620, China.
ORCID-Profile: Xue-Bo Yin
Förderung
- Natural Science Basic Research Plan in Shaanxi Province of China
- National Undergraduate Training Programs for Innovation and Entrepreneurship
- Natural Science Foundation of Fujian Province
- Natural Science Foundation of Chongqing
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing Municipality
Zitieren
APA
Li, Y., Wu, S. Q., Nan, F., Deng, W., Li, K., Jarhen, N., Zhou, Y., Ma, Q., Qu, Y., Chen, C., Ren, Y., & Yin, X. B. (2024). Single‐Atom Iridium Nanozyme‐Based Persistent Luminescence Nanoparticles for Multimodal Imaging‐Guided Combination Tumor Therapy. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202402544
Vancouver
Li Y, Wu SQ, Nan F, Deng W, Li K, Jarhen N, et al. Single‐Atom Iridium Nanozyme‐Based Persistent Luminescence Nanoparticles for Multimodal Imaging‐Guided Combination Tumor Therapy. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202402544
BibTeX
@article{Li2024,
author = {Li, Yang and Wu, Shu-Qi and Nan, Fang and Deng, Wei and Li, Kaixuan and Jarhen, Nur and Zhou, Yitong and Ma, Qianli and Qu, Yuanyuan and Chen, Chaoxiang and Ren, Yujing and Yin, Xue-Bo},
title = {Single‐Atom Iridium Nanozyme‐Based Persistent Luminescence Nanoparticles for Multimodal Imaging‐Guided Combination Tumor Therapy},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202402544}
}
EUVIMED